
News


KMR Group reports that the duration of clinical trials continues to hold steady or increase despite ongoing efforts by biopharmaceutical companies to reduce cycle times.


U.S. Representative Billy Long has introduced legislation to update regulations guiding how drug manufacturers communicate product information.

Randomized Clinical Trials (RCTs) have constituted the foundation for new drug approvals for over fifty years.

This month marks a landmark in the quest for personalized medicine and the growing role of big data in health sciences – from clinical development through tracking patient outcomes long after a therapy has reached the market.

One of the worrisome aspects of the U.S. Open Payments transparency program is that it may discourage doctors from serving as investigators in clinical studies. The two-year-old program requires public disclosure of payments by drug and medical device manufacturers to health care professionals (HCPs) and teaching hospitals for conducting clinical trials, as well as for marketing and consulting activities. But an anomaly in the program credits to the principal investigator (PI) heading up a research site the full payment for managing and carrying out the study at that site.






Tufts CSDD finds drug and diagnostics companies are investing in the development of companion diagnostics that can show that their use in conjunction with personalized therapeutics will lead to positive health outcomes.

An analysis by Life Science Compliance Update of the U.S. government's Open Payments database shows that industry spending on U.S-based clinical research has dropped 32% in the first year-over-year comparison since Open Payments data started to be collected.




Kowa Company Ltd, a Japanese pharmaceutical company, has migrated to Oracle Argus Cloud Service Global and Oracle Argus Cloud Japan.

New faces among the Pharma Industry rise the ranks.

How can you navigate the regulatory triangle safely?


The Jumpstarting Brain Tumor Drug Development Coalition (JBTDDC) announced a new consensus protocol for magnetic resonance imaging (MRI) in brain tumor clinical trials to help assess if a new treatment is effective.


CRO is the first to participate in IACOR’s accreditation pilot.


Cloud-based solution allows investigators to simplify the development of clinical research protocols.



The New England Journal of Medicine recently published results of a multi-center Phase II clinical trial, managed by CTMG.

.png)



.png)



.png)
.png)
